Navigation Links
UH Case Medical Center publishes study on novel treatment for skin lymphoma
Date:1/17/2012

CLEVELAND: Promising findings on a novel combination treatment approach for a chronic type of skin lymphoma are being published today (embargoed for 4 pm) in JAMA's Archives of Dermatology by clinical researchers from Seidman Cancer Center at University Hospitals (UH) Case Medical Center and Case Western Reserve University School of Medicine.

The article outlines findings from a first-of-its-kind study showing that O6-benzylguanine is successful in treating cutaneous T-Cell lymphoma by enhancing the efficacy of topical chemotherapy (carmustine).

"Current therapy for cutaneous T-Cell lymphoma is suboptimal and this new study shows that adding O6-benzylguanine to carmustine is more effective and less toxic to the skin, allowing for more optimal treatments," says Kevin Cooper, MD, Chairman of the Department of Dermatology at UH Case Medical Center and Case Western Reserve University School of Medicine. "This treatment essentially weakens the cancer cells to make the lymphoma more vulnerable to topical chemotherapy and has a lot of potential in alleviating patients' disease burden in this chronic and progressive disease."

Cutaneous T-cell lymphoma is a form of lymphoma which affects the skin and typically relapses and becomes increasingly challenging to treat. The new drug combination offers a potential new option for patients using skin-directed treatments, before the need to undergo systemic chemotherapy.

Clinical researchers at UH Case Medical Center and Case Western Reserve University have been investigating O6-benzylguanine over the past decade and were participants in the original research into its mechanism of action as a cancer treatment potentiator. This study, funded by National Cancer Institute grants to Case Western Reserve University in conjunction with Keryx Pharmaceuticals Inc., is the first to explore the drug's efficacy to intensify treatment for skin lymphoma.

When used alone, carmustine attaches to the DNA in the patient's cancer cells during the replication process, causing the cancer cells to die. Problems sometimes occur when an enzyme clips off the treatment from the DNA, allowing the cancer cells to replicate. O6-benzylguanine inhibits the enzyme from clipping off the carmustine from the DNA, so the drug can complete its mission and kill the cancer cells.

"By adding O6-benzylguanine, we can effectively lower the dosage of the topical treatment, carmustine, and render it less toxic on healthy cells but more effective at killing cancer cells," says Dr. Cooper. "This combination treatment has had excellent initial clinical results and we are following it up with additional ongoing studies."


'/>"/>
Contact: Alicia Reale
alicia.reale@uhhospitals.org
University Hospitals Case Medical Center
Source:Eurekalert

Related medicine news :

1. Surgical robots to provide open-source platform for medical robotics research
2. CCNYs Robert Alfano wins first biomedical optics award
3. CareFirst BCBS and ACP offer new tool to advance development of patient-centered medical homes
4. Use of acupuncture in the US military highlighted in special issue of Medical Acupuncture
5. Lingua franca critical for electronic medical records and health information exchange
6. Self-affirmation may break down resistance to medical screening
7. Society of Interventional Radiology Foundation receives support from Siemens Medical
8. FDA Seeks to Get More Women Into Trials of Medical Devices
9. Experts Urge Limits on Medical Research on Chimpanzees
10. UW Medical Center granted magnet status for excellence in nursing care
11. Nations largest federation of biological and biomedical organizations welcomes 2 new members
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... 2016 , ... The president released a FY 2017 budget request on Tuesday ... of the cost burden to military beneficiaries. , MOAA’s president, retired Air Force ... as including limited quantifiable benefit fixes mixed with numerous beneficiary fee hikes. , “We ...
(Date:2/11/2016)... ... February 11, 2016 , ... Hall Integrative ... gearing up for their simultaneous grand openings in March. All seven practices are ... you’re probably wondering, is reversing diabetes possible? According to this 2011 CNN article ...
(Date:2/11/2016)... ... 2016 , ... Thermi™, a world leader in thermistor-regulated energy ... promotions of Allison Kelly to executive vice president of the company’s new North ... North American capital sales, and Wendy Oseas to vice president of global marketing. ...
(Date:2/11/2016)... ... February 11, 2016 , ... Atlantic Information Services, Inc. ... Model: A Case Study for Plans and Purchasers.” Executives from Intel Corp. and ... Intel on value-based health benefits program Connected Care, will discuss the challenges they ...
(Date:2/11/2016)... ... February 11, 2016 , ... The Commission for Case Manager ... of Commissioners. Individuals interested in volunteer board service are encouraged to apply. The ... settings and across allied health to contribute to its mission and vision. The ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... , Feb. 11, 2016  Attending college is ... those with type 1 diabetes, the journey can be ... schedules, assignments and campus activities, they also manage the ... top of that, many are living away from home ... (Foundation) Lilly Diabetes Tomorrow,s Leaders Scholarship with $100,000 ...
(Date:2/11/2016)... , Feb. 11, 2016 Brain Cancer ... new treatment method at West Cancer Center . ... electric fields to inhibit cancer cell replication causing death ... more than a decade to show a significant extension ... Multiforme (GBM) patients. Currently, West Cancer Center is the ...
(Date:2/11/2016)... 2016  AbbVie, a global biopharmaceutical company, announced ... to provide financial support for exceptional students living ... education goals. Fifteen scholars will be selected to ... The AbbVie Rheumatology Scholarship is currently accepting applications. ... corporate social responsibility, brand and communications, AbbVie. "By ...
Breaking Medicine Technology: